Olanzapine greatly effective in Vomiting Control in children undergoing Chemotherapy

In a new study conducted by Abdul W. Moothedath and team showed that in the delayed period, olanzapine considerably improved total control of vomiting. In the olanzapine group, a much lower proportion of patients required rescue drugs.

The goal of this work was to assess the safety and effectiveness of olanzapine in children following severely emetogenic chemotherapy. The findings of this were published in Journal of Pediatric Hematology/Oncology on 28th January, 2022.

Patients aged 3 to 18 years were randomly allocated to either the olanzapine or placebo groups in this trial. Intravenous ondansetron and dexamethasone were given to all patients 30 minutes before highly emetogenic treatment, followed by oral ondansetron for 48 hours. On days 1 and 2, participants in the olanzapine group got olanzapine once daily, whereas those in the control group received a placebo in the same dosage and timing. The major goal was to compare (a) the complete control rates of vomiting in the delayed phase and (b) the complete control rates of vomiting in the acute and overall phases. The secondary goal was to assess olanzapine's safety and the necessity for emergency drugs.